HUE051288T2 - CMET elleni ellenanyag - Google Patents

CMET elleni ellenanyag

Info

Publication number
HUE051288T2
HUE051288T2 HUE18188726A HUE18188726A HUE051288T2 HU E051288 T2 HUE051288 T2 HU E051288T2 HU E18188726 A HUE18188726 A HU E18188726A HU E18188726 A HUE18188726 A HU E18188726A HU E051288 T2 HUE051288 T2 HU E051288T2
Authority
HU
Hungary
Prior art keywords
cmet antibody
cmet
antibody
Prior art date
Application number
HUE18188726A
Other languages
English (en)
Inventor
Liliane Goetsch
Thierry Wurch
Cedric Bes
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41693124&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE051288(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/IB2008/055663 external-priority patent/WO2010064089A1/en
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of HUE051288T2 publication Critical patent/HUE051288T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
HUE18188726A 2008-12-02 2009-12-02 CMET elleni ellenanyag HUE051288T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/IB2008/055663 WO2010064089A1 (en) 2008-12-02 2008-12-02 Novel anti-cmet antibody
US18450209P 2009-06-05 2009-06-05

Publications (1)

Publication Number Publication Date
HUE051288T2 true HUE051288T2 (hu) 2021-03-01

Family

ID=41693124

Family Applications (3)

Application Number Title Priority Date Filing Date
HUE18188726A HUE051288T2 (hu) 2008-12-02 2009-12-02 CMET elleni ellenanyag
HUE16192250A HUE040553T2 (hu) 2008-12-02 2009-12-02 ANTI-cMET ANTITEST
HUE09771324A HUE035047T2 (hu) 2008-12-02 2009-12-02 ANTI-cMET-ANTITEST

Family Applications After (2)

Application Number Title Priority Date Filing Date
HUE16192250A HUE040553T2 (hu) 2008-12-02 2009-12-02 ANTI-cMET ANTITEST
HUE09771324A HUE035047T2 (hu) 2008-12-02 2009-12-02 ANTI-cMET-ANTITEST

Country Status (39)

Country Link
US (4) US8741290B2 (hu)
EP (4) EP3431502B1 (hu)
JP (3) JP5863458B2 (hu)
KR (1) KR101838299B1 (hu)
CN (2) CN102227446B (hu)
AR (1) AR074439A1 (hu)
AU (3) AU2009328318C1 (hu)
BR (2) BR122019023930B1 (hu)
CA (1) CA2743433C (hu)
CL (2) CL2011001296A1 (hu)
CO (1) CO6382139A2 (hu)
CR (1) CR20110324A (hu)
CY (2) CY1119172T1 (hu)
DK (2) DK3135691T3 (hu)
EC (1) ECSP11011127A (hu)
ES (3) ES2697098T3 (hu)
GE (2) GEP20135930B (hu)
HK (2) HK1190414A1 (hu)
HR (2) HRP20171011T8 (hu)
HU (3) HUE051288T2 (hu)
IL (2) IL213273A0 (hu)
LT (2) LT2370468T (hu)
MA (1) MA32892B1 (hu)
MX (2) MX2011005677A (hu)
MY (2) MY185200A (hu)
NZ (1) NZ593853A (hu)
PE (1) PE20120343A1 (hu)
PH (1) PH12015501515A1 (hu)
PL (3) PL3135691T3 (hu)
PT (3) PT2370468T (hu)
RS (2) RS56204B1 (hu)
RU (2) RU2560257C2 (hu)
SA (2) SA109300720B1 (hu)
SG (2) SG171851A1 (hu)
SI (3) SI2370468T1 (hu)
TN (1) TN2011000216A1 (hu)
TW (2) TWI459964B (hu)
WO (1) WO2010069765A1 (hu)
ZA (1) ZA201105164B (hu)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2014681A1 (en) 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
US8545839B2 (en) * 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody
EP2287197A1 (en) * 2009-08-21 2011-02-23 Pierre Fabre Medicament Anti-cMET antibody and its use for the detection and the diagnosis of cancer
EP2545077B1 (en) 2010-03-10 2018-10-31 Genmab A/S Monoclonal antibodies against c-met
EP2611928B1 (en) 2010-09-03 2016-04-27 Academia Sinica Anti-c-met antibody and methods of use thereof
RU2608644C2 (ru) 2010-11-03 2017-01-23 арДЖЕН-ИКС Н.В. Антитела против белка рецептора с-мет
CN107903325B (zh) 2011-05-16 2021-10-29 埃泰美德(香港)有限公司 多特异性fab融合蛋白及其使用方法
KR101865223B1 (ko) 2011-10-05 2018-06-08 삼성전자주식회사 항 ｃ-Ｍｅｔ 인간화 항체 및 그의 용도
KR20130036993A (ko) * 2011-10-05 2013-04-15 삼성전자주식회사 ｃ-Ｍｅｔ의 ＳＥＭＡ 도메인 내의 에피토프에 특이적으로 결합하는 항체
US9926364B2 (en) 2011-11-03 2018-03-27 Argen-X N.V. Chimeric human-llama antigens and methods of use
KR101463098B1 (ko) * 2011-11-28 2014-11-27 한국생명공학연구원 ｃ-Ｍｅｔ에 대한 인간항체에 약물이 접합된 약물 복합체 및 이의 용도
KR101910601B1 (ko) 2011-12-22 2018-10-23 삼성전자주식회사 면역원성이 제거된 항 ｃ-Ｍｅｔ 인간화 항체 및 그의 용도
WO2013192594A2 (en) * 2012-06-21 2013-12-27 Sorrento Therapeutics Inc. Antigen binding proteins that bind c-met
EP2708556B1 (en) 2012-09-12 2018-11-07 Samsung Electronics Co., Ltd Pharmaceutical composition for the use in a combination therapy for prevention or treatment of c-met or angiogenesis factor induced diseases
ME03486B (me) 2012-10-12 2020-01-20 Medimmune Ltd Pirolobenzodiazepini i njihovi konjugati
CN105209077B (zh) 2013-03-13 2019-06-11 麦迪穆有限责任公司 吡咯并苯并二氮杂卓以及其结合物
KR102049990B1 (ko) * 2013-03-28 2019-12-03 삼성전자주식회사 c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
US9994644B2 (en) 2013-04-30 2018-06-12 Agency For Science, Technology And Research mAB 2 anti-Met antibody
US9567641B2 (en) * 2013-07-03 2017-02-14 Samsung Electronics Co., Ltd. Combination therapy for the treatment of cancer using an anti-C-met antibody
US9717715B2 (en) 2013-11-15 2017-08-01 Samsung Electronics Co., Ltd. Method of combination therapy using an anti-C-Met antibody
EP3083697B1 (en) * 2013-12-20 2019-04-17 Development Center for Biotechnology Alpha-enolase specific antibodies and methods of uses in cancer therapy
US10188746B2 (en) 2014-09-10 2019-01-29 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US20180057595A1 (en) * 2015-03-16 2018-03-01 Celldex Therapeutics, Inc. Anti-MET Antibodies and Methods of Use Thereof
KR102476846B1 (ko) * 2016-02-05 2022-12-12 주식회사 헬릭스미스 항―ｃ―ＭＥＴ 항체 및 이의 용도
US10870701B2 (en) 2016-03-15 2020-12-22 Generon (Shanghai) Corporation Ltd. Multispecific fab fusion proteins and use thereof
LT3458102T (lt) * 2016-05-17 2020-08-25 Abbvie Biotherapeutics Inc. Anti-cmet antikūnų vaisto konjugatai ir jų naudojimo būdai
US10457726B2 (en) 2016-06-30 2019-10-29 University Of Connecticut Antibody and antigen-binding fragment compositions targeting cell surface antigens in tumors and methods of use thereof
JP2019534882A (ja) 2016-10-11 2019-12-05 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ 免疫介在性療法薬を有する抗体−薬物コンジュゲート
RU2741228C2 (ru) * 2016-11-14 2021-01-22 Общество С Ограниченной Ответственностью "Панацела Лабс" Противоопухолевые эффекты вирусного вектора, кодирующего толл-подобный рецептор и агонист толл-подобного рецептора
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
WO2018129029A1 (en) * 2017-01-04 2018-07-12 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
CN109771642B (zh) 2017-11-13 2022-09-20 同济大学苏州研究院 c-MET激动型抗体及其用途
GB201803892D0 (en) * 2018-03-12 2018-04-25 Ultrahuman Six Ltd C-met binding agents
MX2020012418A (es) 2018-05-23 2021-04-28 Adc Therapeutics Sa Adyuvante molecular.
EP3833385A4 (en) * 2018-08-08 2021-12-22 Dragonfly Therapeutics, Inc. PROTEINS THAT BINDING NKG2D, CD16 AND A TUMOR-ASSOCIATED ANTIGEN
CN109541221B (zh) * 2018-10-24 2022-03-22 益善生物技术股份有限公司 一种c-Met特异性抗体、组合物及试剂盒
KR102353568B1 (ko) * 2018-11-14 2022-01-20 주식회사 헬릭스미스 안정성이 향상된 항 c-Met 항체 또는 그의 항원 결합 단편
CN114340684A (zh) 2019-09-16 2022-04-12 瑞泽恩制药公司 用于免疫pet成像的放射性标记的met结合蛋白
US20230372528A1 (en) 2020-10-16 2023-11-23 University Of Georgia Research Foundation, Inc. Glycoconjugates
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
WO2022214517A1 (en) * 2021-04-08 2022-10-13 Byondis B.V. Anti-c-met antibodies and antibody-drug conjugates
UY39743A (es) * 2021-04-29 2022-11-30 Abbvie Inc Conjugados de anticuerpo anti-c-met y fármaco
US20230285394A1 (en) 2022-03-11 2023-09-14 Abbvie Biotherapeutics Inc. Methods of treatment of non-small-cell lung carcinoma using telisotuzummab vedotin and osimertinib

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4424200A (en) 1979-05-14 1984-01-03 Nuc Med Inc. Method for radiolabeling proteins with technetium-99m
US4479930A (en) 1982-07-26 1984-10-30 Trustees Of The University Of Massachusetts Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8924581D0 (en) 1989-11-01 1989-12-20 Pa Consulting Services Bleaching of hair
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5686292A (en) * 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
WO2002055106A2 (en) * 2001-01-09 2002-07-18 Merck Patent Gmbh Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors
BRPI0407446A (pt) * 2003-02-13 2006-01-31 Pharmacia Corp Anticorpos para c-met para o tratamento de cânceres
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
AU2004298483A1 (en) * 2003-12-11 2005-06-30 Genentech, Inc. Methods and compositions for inhibiting c-met dimerization and activation
NZ552485A (en) * 2004-08-05 2009-11-27 Genentech Inc Humanized anti-cmet antagonists
US8008443B2 (en) * 2005-04-26 2011-08-30 Medimmune, Llc Modulation of antibody effector function by hinge domain engineering
NO345593B1 (no) * 2005-07-18 2021-05-03 Amgen Inc Humane anti-B7RP1 nøytraliserende antistoffer
WO2007016285A2 (en) * 2005-07-28 2007-02-08 Novartis Ag M-csf specific monoclonal antibody and uses thereof
WO2007126799A2 (en) 2006-03-30 2007-11-08 Novartis Ag Compositions and methods of use for antibodies of c-met
EP2014681A1 (en) * 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
US8545839B2 (en) 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody

Also Published As

Publication number Publication date
JP2016117721A (ja) 2016-06-30
HRP20171011T1 (hr) 2017-09-22
RS56204B1 (sr) 2017-11-30
JP6074018B2 (ja) 2017-02-01
MY185200A (en) 2021-04-30
CR20110324A (es) 2011-07-28
LT3135691T (lt) 2018-11-12
SI2370468T1 (sl) 2017-08-31
CO6382139A2 (es) 2012-02-15
SA112331005B1 (ar) 2015-09-13
DK2370468T3 (en) 2017-06-19
GEP20146207B (en) 2014-12-10
MA32892B1 (fr) 2011-12-01
US20110239316A1 (en) 2011-09-29
BRPI0923231A2 (pt) 2016-01-26
TWI523866B (zh) 2016-03-01
SI3135691T1 (sl) 2018-12-31
CN102227446B (zh) 2015-10-21
CL2011001296A1 (es) 2011-08-26
AU2017203929A1 (en) 2017-07-06
RU2560257C2 (ru) 2015-08-20
PL2370468T3 (pl) 2017-09-29
GEP20135930B (en) 2013-10-10
TWI459964B (zh) 2014-11-11
JP2012510280A (ja) 2012-05-10
ES2629855T3 (es) 2017-08-16
HRP20181868T1 (hr) 2019-01-11
CA2743433A1 (en) 2010-06-24
US20130109841A1 (en) 2013-05-02
CN102227446A (zh) 2011-10-26
SG171851A1 (en) 2011-07-28
WO2010069765A1 (en) 2010-06-24
MX341014B (es) 2016-08-03
PL3431502T3 (pl) 2020-12-28
KR20110097839A (ko) 2011-08-31
US8765128B2 (en) 2014-07-01
HK1190414A1 (zh) 2014-07-04
RS58018B1 (sr) 2019-02-28
IL231525A0 (en) 2014-04-30
TW201446805A (zh) 2014-12-16
IL231525B (en) 2019-07-31
HRP20171011T8 (hr) 2019-01-25
IL213273A0 (en) 2011-07-31
ECSP11011127A (es) 2011-07-29
SA109300720B1 (ar) 2013-05-25
EP3431502B1 (en) 2020-07-22
JP6309657B2 (ja) 2018-04-11
JP5863458B2 (ja) 2016-02-16
BR122019023930B1 (pt) 2021-05-04
PL3135691T3 (pl) 2019-02-28
AU2016200725C1 (en) 2017-10-19
RU2015127471A (ru) 2018-12-21
ES2827277T3 (es) 2021-05-20
AU2009328318A1 (en) 2011-07-28
AU2009328318B2 (en) 2015-11-05
JP2017099392A (ja) 2017-06-08
BRPI0923231B1 (pt) 2020-04-28
MX2011005677A (es) 2011-06-30
EP3431502A1 (en) 2019-01-23
AU2016200725A1 (en) 2016-02-25
CY1121025T1 (el) 2019-12-11
PE20120343A1 (es) 2012-04-16
US8741290B2 (en) 2014-06-03
TN2011000216A1 (en) 2012-12-17
CN103351438A (zh) 2013-10-16
HUE035047T2 (hu) 2018-05-02
US8747850B2 (en) 2014-06-10
RU2011124751A (ru) 2013-01-10
US20130109840A1 (en) 2013-05-02
EP3135691B1 (en) 2018-08-15
CN103351438B (zh) 2016-04-20
AU2016200725B2 (en) 2017-05-25
ZA201105164B (en) 2012-03-28
KR101838299B1 (ko) 2018-03-14
AU2009328318C1 (en) 2017-11-02
AU2017203929B2 (en) 2019-03-28
PT2370468T (pt) 2017-07-13
HUE040553T2 (hu) 2019-03-28
DK3135691T3 (en) 2018-11-19
CA2743433C (en) 2019-06-11
EP3135691A1 (en) 2017-03-01
CY1119172T1 (el) 2018-02-14
MY192567A (en) 2022-08-29
CL2014000181A1 (es) 2014-07-25
LT2370468T (lt) 2017-07-10
HK1162536A1 (zh) 2012-08-31
ES2697098T3 (es) 2019-01-22
NZ593853A (en) 2013-03-28
AR074439A1 (es) 2011-01-19
US8729249B2 (en) 2014-05-20
PT3135691T (pt) 2018-11-27
PT3431502T (pt) 2020-10-29
EP2370468A1 (en) 2011-10-05
EP2370468B1 (en) 2017-04-05
TW201023892A (en) 2010-07-01
PH12015501515A1 (en) 2015-12-14
SG187518A1 (en) 2013-02-28
US20130109844A1 (en) 2013-05-02
BRPI0923231B8 (pt) 2021-05-25
EP3757132A1 (en) 2020-12-30
SI3431502T1 (sl) 2021-01-29

Similar Documents

Publication Publication Date Title
HRP20181868T1 (hr) Anti-cmet antitijelo
IL276622A (en) Antibody formulation
EP2241578A4 (en) ANTI-CLDN6 ANTIBODIES
ZA201102119B (en) Improved antibody libraies
EP2358392A4 (en) ANTIBODY FORMULATION
GB0821100D0 (en) Antibodies
EP2337798A4 (en) BSA-SPECIFIC ANTIBODIES
IL207581A0 (en) Anti-tyrp1 antibodies
GB0911770D0 (en) Antibody
GB0817621D0 (en) Antibody
GB0817622D0 (en) Antibody
GB0806230D0 (en) Antibodies
GB0823562D0 (en) Antibodies